• Publications
  • Influence
A randomized phase II study of BB-10010: a variant of human macrophage inflammatory protein-1alpha for patients receiving high-dose etoposide and cyclophosphamide for malignant lymphoma and breast
Macrophage inflammatory protein-1alpha (MIP-1alpha) is a chemokine that can inhibit the cell cycle progression of both primitive haemopoietic and epidermal progenitor cells. This property couldExpand
  • 4
  • 1
Pulmonary pharmacology of a novel, smooth muscle-selective muscarinic antagonist in vivo.
The need for a smooth muscle-selective muscarinic antagonist that could provide oral bronchodilator activity with minimal side effects has led to the discovery ofExpand
  • 12
Hypotensive effect of an M2-selective muscarinic antagonist in anaesthetized guinea-pigs.
1. In order to determine an involvement of muscarinic M2 receptors in the regulation of systemic arterial blood pressure, we investigated the cardiovascular effects of the M2-selective antagonistExpand
  • 6
A randomized phase II study of BB‐10010: a variant of human macrophage inflammatory protein‐1α for patients receiving high‐dose etoposide and cyclophosphamide for malignant lymphoma and breast cancer
Macrophage inflammatory protein‐1α (MIP‐1α) is a chemokine that can inhibit the cell cycle progression of both primitive haemopoietic and epidermal progenitor cells. This property could potentiallyExpand
  • 13
Methoctramine induces nonspecific airway hyperresponsiveness in vivo.
We investigated the effects of subtype-selective muscarinic receptor antagonists upon aerosol antigen-induced bronchoconstriction in anesthetized guinea pigs. Neither pirenzepine (muscarinic M1Expand
  • 2